CJC-1295 for Injury Recovery: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
CJC-1295 in injury recovery is a moderate use case stacked rather than primary. The mechanism contributes: elevated GH and IGF-1 support tissue repair, collagen synthesis, and the anabolic environment that injured tissue needs to remodel. But CJC is not a tissue-specific tool the way BPC-157 and TB-500 are. It works on the systemic recovery environment rather than the local repair work at the injury site.
The clinical pattern in user reports tracks the mechanism. CJC contributes most to serious injuries where systemic recovery support layers usefully onto the local peptide work: major orthopedic procedures, severe soft-tissue injuries, chronic non-healing tissue where the body overall repair capacity has degraded with age. Anecdotally, users running CJC alongside BPC-157 and TB-500 report better systemic recovery (less fatigue, faster training return) but the peptide does not accelerate the local healing curve directly the way the tissue-specific compounds do.
Used by many in the recovery / biohacking space who are stacking for non-trivial injuries and want the GH-pathway support on top of the local peptide work. Run this as a tactical, legal performance layer at the systemic level. For straightforward soft-tissue injuries that respond to BPC-157 and TB-500 alone, adding CJC does not deliver enough additional value to justify the dosing complexity. For complex post-surgical recoveries and chronic stubborn cases, the systemic GH layer earns its place.
Dose for injury recovery
CJC-1295 with DAC: 1 mg subcutaneous once weekly during the recovery window. Conservative dose because the goal here is supporting the systemic recovery environment, not pharmacological GH elevation. Without DAC: 100 mcg per dose, 1 to 2 times daily. Stack with Ipamorelin at the same dose for GH-pulse amplification.
Cycle length
8 to 12 weeks aligned with the local peptide protocol (BPC-157, TB-500) and the physio timeline. Start CJC at the same window as the local peptides (typically 1 to 2 weeks post-injury or post-op after clearance). Cycle off when the local protocol completes.
Stack pairings
Commonly stacked with BPC-157, TB-500 and Ipamorelin.
Expected timeline
Week 1–3: improved sleep quality and recovery between rehab sessions. Energy improves before the visible recovery does. Week 3–8: deeper systemic recovery support shows up; users typically report less cumulative fatigue from the rehab and training loads. Week 8–12: cumulative effect on the recovery timeline becomes visible. Most hit physio milestones modestly faster than they would without the CJC layer.
Common mistakes
- Running CJC alone for injury recovery. The peptide supports systemic recovery, not local tissue repair. Without BPC-157, TB-500, or both, the tissue-specific work is missing.
- Starting CJC immediately post-op without clearance. The surgical team needs to clear systemic GH support the same way they clear other peptide interventions. Discuss timing before adding to the protocol.
- Adding CJC for trivial injuries that BPC-157 and TB-500 already handle. The dosing complexity does not pay back. Reserve CJC for serious cases.
- Expecting CJC to accelerate the local healing curve. It does not. The systemic recovery environment improves; the local tissue work is still the job of BPC-157 and TB-500.